Dermorphin

Dermorphin is a naturally occurring opioid peptide first isolated from the skin of the Amazonian frog Phyllomedusa sauvagei Amino acid composition and sequence of dermorphin, a novel opiate-like peptide from the skin of Phyllomedusa sauvagei. Its sequence, Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, contains an unusual D-alanine at position 2. That D-amino acid is required for high-affinity binding at mu-opioid receptors (MOR), the same receptors activated by morphine Structural requirements for dermorphin opioid receptor binding+1. In animal assays, dermorphin is far more potent than morphine for pain relief Synthesis and properties of dermorphin and an analog of beta-endorphin containing the dermorphin sequence+1. A historical 1985 trial tested intrathecal dermorphin for postoperative pain, but clinical development did not continue Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. Today the compound is mainly a research probe for opioid signaling and an analyte in anti-doping methods Elucidating important factors and corresponding method optimization for sensitive detection of small peptide drugs in human urine by solid-phase extraction and UPLC-HRMS: The influence of MS scan modes, protein precipitants, and ammonium formate+1.

Dermorphin binds and activates the mu-opioid receptor (MOR) through its N-terminal Tyr-D-Ala-Phe message domain. Replacing the D-alanine at position 2 with L-alanine lowers receptor affinity roughly 5,000-fold Structural requirements for dermorphin opioid receptor binding. When MOR is activated, it is a G protein-coupled receptor that reduces cyclic AMP, opens GIRK potassium channels, and reduces calcium entry. The net effect is reduced excitability in pain-transmitting neurons IUPHAR themed review: Opioid efficacy, bias, and selectivity+1. Unlike morphine, dermorphin's antinociception depends on receptor internalization Opioid receptor internalization contributes to dermorphin-mediated antinociception. The compound has biphasic effects: low doses stimulate respiration and movement through mu1 receptors, while higher doses depress respiration and cause catalepsy through mu2 receptors Respiratory and locomotor stimulation by low doses of dermorphin, a mu1 receptor-mediated effect+1. Some dermorphin-derived tetrapeptides, such as DALDA, are hydrophilic and act mainly outside the brain to reduce pain with fewer central side effects Peripheral mu-opioid receptor activation by dermorphin [D-Arg2, Lys4] (1-4) amide alleviates behavioral and neurobiological aberrations in rat model of chemotherapy-induced neuropathic pain+2.

Pain relief

Dermorphin and related analogs reduce pain in animal models, including tail-flick, spinal nerve ligation, chemotherapy-induced neuropathy, burn pain, and frostbite pain Synthesis and properties of dermorphin and an analog of beta-endorphin containing the dermorphin sequence+4. In humans, intrathecal dermorphin inhibited the spinal nociceptive flexion reflex, confirming central opioid action Dermorphin inhibits spinal nociceptive flexion reflex in humans. A historical RCT reported postoperative analgesia superior to morphine, but no modern trials exist Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation.

Other documented effects

• Respiration: Low doses stimulate breathing, while higher doses depress it and can trigger apnea Respiratory and locomotor stimulation by low doses of dermorphin, a mu1 receptor-mediated effect+1.
• Central suppression: Catalepsy, sedation, and seizures after high central doses have been described in animal studies Dermorphin-related peptides from the skin of Phyllomedusa bicolor and their amidated analogs activate two mu opioid receptor subtypes that modulate antinociception and catalepsy in the rat+1.
• Gastrointestinal slowing: Dermorphin inhibits gastric emptying and GI transit through central and pituitary-adrenal pathways Effects of dermorphin on gastrointestinal transit in rats+1.
• Endocrine changes: Dermorphin elevates prolactin in rats and in early human studies Dermorphin Stimulates Prolactin Secretion in the Rat+1.
• Tolerance and dependence: Repeated administration produces tolerance, physical dependence, and cross-tolerance with morphine Tolerance and physical dependence induced by dermorphin in rats+1.

Human dermorphin protocol data are limited to a single historical intrathecal trial for postoperative pain, reported in a 1985 review; the exact dose and phase schedule are not specified in the available source Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. Most modern protocol work uses the peripherally restricted analog DALDA, tested subcutaneously in rats at 1 to 10 mg/kg across chemotherapy-induced neuropathy, spinal nerve ligation, burn pain, frostbite pain, and spinal cord injury models Peripheral mu-opioid receptor activation by dermorphin [D-Arg2, Lys4] (1-4) amide alleviates behavioral and neurobiological aberrations in rat model of chemotherapy-induced neuropathic pain+4. These animal milligram-per-kilogram doses do not translate directly to human protocols.

Research-grade lyophilized dermorphin is typically prepared in sterile diluent for in vivo studies, but the source documents do not define a validated human cycle. Community-derived discussions mention short on/off cycles for native dermorphin and longer cycles for DALDA, but no dose data accompany them.

Dermorphin is water-soluble and reconstitutes readily in bacteriostatic water or sterile water for injection. Historical intrathecal use requires a sterile, preservative-free diluent Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. Research handling guidance describes injecting diluent slowly against the vial wall and rolling the vial gently instead of shaking. Keep lyophilized dermorphin at -20 degrees C protected from light and moisture, and refrigerate reconstituted material at 2 to 8 degrees C. The major metabolite of dermorphin in human liver microsomes and zebrafish is the N-terminal tetrapeptide YAFG-OH, which indicates the peptide remains subject to enzymatic degradation after reconstitution Evaluation of Dermorphin Metabolism Using Zebrafish Water Tank Model and Human Liver Microsomes. Use the reconstitution calculator below for volume and dose arithmetic.

Documented interactions come mostly from animal studies.

• Opioid antagonists: Naloxone reverses dermorphin analgesia and catalepsy, while methylnaltrexone blocks peripheral analgesia from DALDA Antagonism of dermorphin-induced catalepsy with naloxone, TRH-analog CG3703 and the benzodiazepine antagonist, Ro 15-1788+2.
• Fentanyl and other opioids: Dermorphin pretreatment blocks fentanyl-induced apnea in rats, likely through mu1 receptor desensitization Dermorphin blocks apneic response to intravenous bolus injection of fentanyl. Additive respiratory depression is still possible because both are mu-opioid receptor agonists.
• CNS depressants: No modern interaction studies exist, but sedatives and anesthetics should be expected to add to respiratory depression Respiratory and Cardiovascular Activity of LENART01, an Analgesic Dermorphin-Ranatensin Hybrid Peptide, in Anesthetized Rats.
• Peripheral cannabinoids: DALDA and the peripheral cannabinoid CB-13 synergistically reduced neuropathic mechanical hypersensitivity in mice Peripherally restricted cannabinoid and mu-opioid receptor agonists synergistically attenuate neuropathic mechanical hypersensitivity in mice.
• Dermorphin-dynorphin analogs: Central dermorphin-dynorphin analogs produced antidepressant-like effects through mu1 and kappa receptors in mice Intracerebroventricular Administration of Dermorphin-Dynorphin Analogs Producing Antidepressant-Like Effects through Activation of μ<sub>1</sub>- and κ-Opioid Receptors in Mice.

No controlled human study defines a dermorphin cycle. The 1985 trial tested a single intrathecal exposure for postoperative pain Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. Chronic dermorphin produces tolerance and physical dependence in rats, with cross-tolerance to morphine Tolerance and physical dependence induced by dermorphin in rats+1. On that basis, research protocols and community discussions favor short exposures and off periods, but no human dosing cycle is validated. Peripherally restricted analogs such as DALDA reduce central effects, but repeated use still produces tolerance Activation of Peripheral μ-opioid Receptors by Dermorphin [D-Arg2, Lys4] (1-4) Amide Leads to Modality-preferred Inhibition of Neuropathic Pain+1. The source documents mention a community-derived pattern of 7 to 14 days on and at least 14 days off for native dermorphin, and 4 to 6 weeks on with 2 to 4 weeks off for DALDA, but without dose data.

Dermorphin is not a standard regenerative peptide stacker, but a few combinations appear in the literature.

• DALDA plus peripheral cannabinoids: Synergistic pain relief and reduced motor impairment in mice Peripherally restricted cannabinoid and mu-opioid receptor agonists synergistically attenuate neuropathic mechanical hypersensitivity in mice.
• Dermorphin plus ranatensin hybrids: LENART01 combines dermorphin MOR activity with ranatensin-like action, showing antinociception with less respiratory depression and fewer withdrawal signs in animal models Respiratory and Cardiovascular Activity of LENART01, an Analgesic Dermorphin-Ranatensin Hybrid Peptide, in Anesthetized Rats+1.
• Dermorphin plus dynorphin: Central dermorphin-dynorphin analogs produced antidepressant-like effects via mu1 and kappa receptors in mice Intracerebroventricular Administration of Dermorphin-Dynorphin Analogs Producing Antidepressant-Like Effects through Activation of μ<sub>1</sub>- and κ-Opioid Receptors in Mice.
• Dermorphin/substance P hybrid: Improved wound healing in diabetic rats when applied topically with keratin scaffolds The analgesic hybrid of dermorphin/substance P and analog of enkephalin improve wound healing in streptozotocin-induced diabetic rats.

No direct interaction data exist for dermorphin with BPC-157, TB-500, or other regenerative peptides, so separate injection sites and times would be the cautious research approach.

Dermorphin is not FDA-approved for any indication, and no modern marketing authorization is documented in the sources Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. It is not developed as a pharmaceutical. In sport, dermorphin is banned in equine sport and identified as an analyte in human anti-doping research; annual WADA banned-substance reviews address peptide hormone detection Pharmacokinetics and pharmacodynamics of dermorphin in the horse+3. A seized unlabelled vial containing [Dmt1]-DALDA and its first detection in horse urine show diversion and equine doping relevance Identification of the dermorphin tetrapeptide [Dmt(1) ]-DALDA in a seized unlabelled vial and its first detection in horse urine: A case report. Human use outside research would be unapproved in most jurisdictions.

Dermorphin carries opioid-class risks.

• Respiratory depression and apnea: Intravenous bolus dermorphin triggered immediate apnea in rats, and a hybrid caused apnea in 70 percent of anesthetized rats Dermorphin blocks apneic response to intravenous bolus injection of fentanyl+1. Central doses reduce minute volume Respiratory and locomotor stimulation by low doses of dermorphin, a mu1 receptor-mediated effect.
• Central nervous system suppression: Catalepsy, stupor, and dose-dependent sedation occur in animal studies Dermorphin-related peptides from the skin of Phyllomedusa bicolor and their amidated analogs activate two mu opioid receptor subtypes that modulate antinociception and catalepsy in the rat. Intracerebroventricular dermorphin triggers hippocampal seizures Search for the Structures Initiating Seizures Triggered by Intraventricular Injection of the μ opioid Agonist Dermorphin in Rats.
• Kambo toxicity: Dermal exposure to Phyllomedusa bicolor secretion containing dermorphin has caused acute demyelinating polyneuropathy Acute polyneuropathy associated with Kambo poisoning: An unusual case report and fatal hyponatremia with cerebral edema Shamanic Kambô Frog Hyponatremic Toxicity Leading to Brain Death: A Case Report.
• Endocrine and GI effects: Prolactin elevation and GI slowing are documented The effects of dermorphin on the endocrine system in man+1.
• Tolerance and dependence: Repeated dosing produces physical dependence in rats Tolerance and physical dependence induced by dermorphin in rats+1.

No modern human safety data exist. The narrow therapeutic ratio and central opioid toxicity make research handling important.